All In Biotech

Drug Trial Radar · NCT06911034

Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women

Comparison of Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anemia in Pregnant Women

Last checked: Nov 20, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Feb 1, 2024

Primary completion

Jul 31, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
CMH Multan Institute of Medical SciencesGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial aimed to determine whether intravenous ferric carboxymaltose is more useful than iron sucrose for treating anemia in pregnant women. The main question it aimed to answer was: Is intravenous ferric carboxymaltose is more useful than iron sucrose for treating iron deficiency anemia in pregnant women. Sixty pregnant women with iron deficiency anemia were enrolled to one of two intravenous treatments. * Participants in ferrous carboxymaltose group received a maximum dose of 1000 mg per sitting diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. * Participants in iron sucrose group were administered an infusion of 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week.

Conditions

  • Iron Deficiency Anemia (IDA)
  • Pregnancy

Interventions

  • Iron CarboxymaltoseDrug

    In ferrous carboxymaltose treatment maximum dose per sitting was 1000 mg, diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.

  • Iron Sucrose InjectionDrug

    Iron sucrose infusion was administered as 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in hemoglobinTime frame: After three weeks of completing parenteral iron therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cmh Multan Institute of Medical Sciences

    Multan, Punjab Province, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.